New drug SHR6508 aims to tame hormone imbalance in dialysis patients
NCT ID NCT06434961
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new drug called SHR6508 in 498 adults on hemodialysis who have secondary hyperparathyroidism, a condition where the parathyroid glands make too much hormone. The drug is given during dialysis and was compared to an existing oral medication, cinacalcet. The goal was to see if SHR6508 can safely lower parathyroid hormone levels by at least 30%.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SHR6508 (a drug given intravenously during dialysis to lower parathyroid hormone levels)
- What this could lead to
- If successful, SHR6508 could offer a new treatment option for controlling secondary hyperparathyroidism in kidney dialysis patients, potentially with fewer side effects than current therapies.
- What could go wrong
- This is a completed Phase 3 trial, but results are not yet published. The drug may not prove superior to existing treatments like cinacalcet, and side effects such as nausea and vomiting are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SECONDARY HYPERPARATHYROIDISM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, 510000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Dialysis drug showdown: which vitamin d works best?
- New blood test could end painful bone biopsies for kidney disease patients
- New blood test may reveal bone health in kids on dialysis
- Tiny study tracks kidney Drug's exit route in dialysis patients
- New hope for kids with kidney disease: experimental vitamin d pill enters trial
- New drug aims to tame parathyroid glands in dialysis patients